CESSATECH A/S DK -20 (8GN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CESSATECH A/S DK -20 (8GN) has a cash flow conversion efficiency ratio of -0.361x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.27 Million ≈ $-3.83 Million USD) by net assets (€9.06 Million ≈ $10.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CESSATECH A/S DK -20 stock valuation for the company's overall valuation and market capitalisation.
CESSATECH A/S DK -20 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how CESSATECH A/S DK -20's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CESSATECH A/S DK -20 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CESSATECH A/S DK -20 ranked by their cash flow conversion efficiency. See debt repayment capacity of CESSATECH A/S DK -20 to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
0.080x |
|
Fold Holdings, Inc. Class A Common Stock
NASDAQ:FLD
|
-0.181x |
|
Tvardi Therapeutics, Inc.
NASDAQ:TVRD
|
-0.404x |
|
Bluglass Ltd
AU:BLG
|
0.000x |
|
DongKoo Bio & Pharma Co. Ltd.
KQ:006620
|
0.031x |
|
Nissan
TA:NISA
|
0.039x |
|
Honey Badger Silver Inc
V:TUF
|
-0.508x |
|
BIOCERES CROP SOL.
F:0G4
|
0.163x |
Annual Cash Flow Conversion Efficiency for CESSATECH A/S DK -20 (2021–2025)
The table below shows the annual cash flow conversion efficiency of CESSATECH A/S DK -20 from 2021 to 2025. View 8GN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €12.16 Million ≈ $14.21 Million |
€-17.58 Million ≈ $-20.55 Million |
-1.446x | -66.04% |
| 2024-12-31 | €8.27 Million ≈ $9.67 Million |
€-7.21 Million ≈ $-8.43 Million |
-0.871x | -108.37% |
| 2023-12-31 | €-1.92 Million ≈ $-2.24 Million |
€-19.97 Million ≈ $-23.35 Million |
10.406x | +1772.25% |
| 2022-12-31 | €23.86 Million ≈ $27.89 Million |
€-14.85 Million ≈ $-17.36 Million |
-0.622x | -61.62% |
| 2021-12-31 | €26.24 Million ≈ $30.68 Million |
€-10.10 Million ≈ $-11.81 Million |
-0.385x | -- |
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-c… Read more